Nilotinib Teva

Nilotinib, the active ingredient in Nilotinib Teva, is a tyrosine kinase inhibitor presented as a tablet for oral use. It targets the BCR‑ABL protein and is used to treat chronic myeloid leukemia in adult patients. It is approved in the European Union and is indicated for patients with chronic phase or accelerated phase disease who are resistant or intolerant to prior therapy.

GNH USA supplies Nilotinib Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Nilotinib acts on the BCR‑ABL tyrosine kinase pathway, a key driver in chronic myeloid leukemia. - Chronic phase CML: reduces leukemic cell proliferation and achieves deep molecular response. - Accelerated phase CML: provides disease control in patients resistant or intolerant to prior therapy. - CML after imatinib resistance or intolerance: offers an alternative targeted treatment option.

Nilotinib is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea - Diarrhea - Rash - Fatigue

Serious or Rare Side Effects: - QT interval prolongation - Pancreatitis - Hepatic toxicity

When prescribing nilotinib, clinicians should observe several precautionary measures to minimize risk. - ECG monitoring: assess QT interval before initiation and periodically during therapy. - Liver function tests: monitor transaminases and bilirubin regularly. - Blood counts: perform complete blood count to detect neutropenia or thrombocytopenia. - Concomitant QT‑prolonging agents: avoid co‑administration whenever possible. - Hepatic impairment: use with caution and consider dose adjustment in moderate to severe liver disease. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Nilotinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise nilotinib levels and risk of QT prolongation. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): can lower nilotinib exposure and reduce efficacy. - Other QT‑prolonging drugs (e.g., amiodarone, sotalol): increase the chance of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Digoxin: nilotinib may increase digoxin concentrations; monitor serum levels. - Warfarin: potential alteration of INR; check coagulation parameters regularly.